Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Achieve Life Sciences, Inc. (ACHV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.9500-0.0400 (-0.80%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close4.9900
Open4.9500
Bid4.5000 x 800
Ask5.0500 x 1800
Day's Range4.9500 - 5.0550
52 Week Range4.8100 - 10.0900
Volume38,025
Avg. Volume28,970
Market Cap47.925M
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-3.6560
Earnings DateAug 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACHV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Achieve Life Sciences, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • GlobeNewswire

    Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022

    SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its second quarter financial results and provide an update on the cytisinicline development program on Thursday, August 11, 2022, at 4:30 PM EDT. To access the webcast, please use the

  • GlobeNewswire

    Achieve Life Sciences Announces Granting of New Hire Inducement Awards

    SEATTLE and VANCOUVER, British Columbia, July 01, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued inducement grants of stock options to two new employees. Achieve’s Board of Directors approved the new employment inducement grants to purchase an aggregate of 15,000 shares of Ach

  • GlobeNewswire

    Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation

    SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of subjects for the ORCA-V1 Phase 2 clinical trial. ORCA-V1 will evaluate the efficacy and safety of 3mg cytisinicline dosed 3 times daily compared to placebo in approximately 150 a

Advertisement
Advertisement